Drug Pricing in Canada

Lexchin, Joel

doi:10.1007/978-3-319-12169-7_2

Cited by 2 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the UK follows profit sharing and reference system, Canada uses mixed pricing system, Germany uses internal and external reference pricing system, and Iran uses reference and cost plus pricing system (Table 3). [ 22,65–75 ]…”

Section: Resultsmentioning

confidence: 99%

Why healthcare market needs government intervention to improve access to essential medicines and healthcare efficiency: a scoping review from pharmaceutical price regulation perspective

Sorato

Davari

Asl

et al. 2020

Journal of Pharmaceutical Health Services Research

View full text Add to dashboard Cite

Background Access to quality essential medicines at affordable price to patients in the healthcare market is one of the main goals of universal health coverage and health‐related sustainable development goals. Healthcare market is imperfect, and the government cannot ensure access to essential medicines if the market is left to operate under invisible hand control. This scoping review was conducted with intention to provide the clear picture on impact of pharmaceutical price regulation on access to essential medicines, drug innovation and launching. Methods We searched articles written in the English language since January 2000 from PubMed, Embase, Scopus, Ovid/Medline and Google scholar with systematic search query. Results Access to essential medicines, which is defined in terms of availability, affordability, accessibility, acceptability and quality of drugs, can be improved by pharmaceutical price regulation. Countries can use different price regulation strategies based on their healthcare objectives and priority healthcare needs. Country‐specific pharmaceutical price regulation could not significantly affect drug innovation and launching. However, supportive strategies such as open public funding for drug innovation research, providing innovation awards and strong patent rights can counterbalance the effect of price regulation on innovation and drug development research in developed countries. Conclusion Regulating pharmaceutical pricing system is one of the key strategies to ensure access to essential medicines. Countries that have implemented pharmaceutical price regulation system (Germany, the UK, Canada and Iran) have achieved better access to essential medicines. However, the US and Ethiopian health systems that are unregulated concerning pharmaceutical pricing had a great challenge of affordability of essential medicines. Therefore, setting country‐specific pharmaceutical price regulation system along with additional strategies to improve drug innovation is critical to ensure access to essential medicines.

show abstract

Section: Resultsmentioning

confidence: 99%

Why healthcare market needs government intervention to improve access to essential medicines and healthcare efficiency: a scoping review from pharmaceutical price regulation perspective

Sorato

Davari

Asl

et al. 2020

Journal of Pharmaceutical Health Services Research

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7] Health system expenditure on prescription drugs has also increased in many countries, often growing faster than other health system costs. [5][6][7][8][9][10][11][12][13][14] Therefore, implementing universal pharmacare can enhance equitable access to needed care and medicines, which is central to the ongoing debate about the need for a national pharmacare program in Canada. 11 Although Canada's provincial and territorial health systems provide a single-payer system with coverage for medically necessary hospital and physician-based care, this universality does not extend to outpatient prescription medications.…”

mentioning

confidence: 99%

“…[4][5][6] Children and youth are a vulnerable population, and studies that have investigated coverage variation have shown that younger adults are the most disadvantaged in coverage. [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] In…”

mentioning

confidence: 99%

The impact of OHIP+ pharmacare on use and costs of public drug plans among children and youth in Ontario: a time-series analysis

Miregwa

Holbrook

Law

et al. 2022

cmajo

View full text Add to dashboard Cite

Universal health coverage promotes access to necessary care and protects patients from health-related financial hardship that may affect health outcomes. The World Health Organization declared that governments are obligated to promote universal coverage of essential health care services, including prescription drugs. [1][2][3][4] Given the importance of reducing out-of-pocket spending for prescription drugs, universal access to affordable, safe and appropriately prescribed treatments is an important goal for health systems in all countries. 2-5 However, approaches to universal health coverage for prescription medications or universal pharmacare varies according to the population covered (who), health products and technologies (what) and the extent of coverage (proportion of direct costs covered). The amount spent on prescription drugs, including per capita spending, has significantly increased over time. [4][5][6][7] Health system expenditure on prescription drugs has also increased in many countries, often growing faster than other health system costs. [5][6][7][8][9][10][11][12][13][14] Therefore, implementing universal pharmacare can enhance equitable access to needed care and medicines, which is central to the ongoing debate about the need for a national pharmacare program in Canada. 11 Although Canada's provincial and territorial health systems provide a single-payer system with coverage for medically necessary hospital and physician-based care, this universality does not extend to outpatient prescription medications. [2][3][4][5] Instead, prescription drugs are funded by a fragmented patchwork of public and private drug plans that varies by province and leaves many Canadians with little or no drug coverage. [4][5][6] Children and youth are a vulnerable population, and studies that have investigated coverage variation have shown that younger adults are the most disadvantaged in coverage. [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] In

show abstract

Drug Pricing in Canada

Cited by 2 publications

References 23 publications

Why healthcare market needs government intervention to improve access to essential medicines and healthcare efficiency: a scoping review from pharmaceutical price regulation perspective

Why healthcare market needs government intervention to improve access to essential medicines and healthcare efficiency: a scoping review from pharmaceutical price regulation perspective

The impact of OHIP+ pharmacare on use and costs of public drug plans among children and youth in Ontario: a time-series analysis

Contact Info

Product

Resources

About